Incyte Corp (INCY) Receives a Buy from Cowen & Co.


In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on Incyte Corp (INCY). The company’s shares opened today at $76.30.

According to TipRanks.com, Frahm is a 3-star analyst with an average return of 4.4% and a 58.5% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Applied Therapeutics Inc.

Incyte Corp has an analyst consensus of Moderate Buy, with a price target consensus of $85.50.

See today’s analyst top recommended stocks >>

Based on Incyte Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $102 million. In comparison, last year the company had a GAAP net loss of $41.14 million.

Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts